Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology

Acta Neuropathologica

Volumn 133, Issue 2, 2017, Pages 303-319

  Dzamko, Nicolas ^a,b   Gysbers, Amanda ^a   Perera, Gayathri ^a   Bahar, Anita ^a   Shankar, Amrita ^a,b   Gao, Jianqun ^a,b   Fu, YuHong ^a,b   Halliday, Glenda M ^a,b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Autophagy; Inflammation; Parkinson s disease; Toll like receptor; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; SEQUESTOSOME 1; TOLL LIKE RECEPTOR 2; TLR2 PROTEIN, HUMAN;

ADULT; AGED; ANTERIOR CINGULATE; ARTICLE; AUTOPHAGY; BRAIN REGION; BRAIN TISSUE; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPEROXIDASE STAINING; INDUCED PLURIPOTENT STEM CELL; LEWY BODY; LYSOSOME; MICROGLIA; NERVE CELL; OCCIPITAL CORTEX; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BRAIN; FEMALE; IMMUNOLOGY; INFLAMMATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BRAIN; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PARKINSON DISEASE; TOLL-LIKE RECEPTOR 2;

EID: 84997285708     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-016-1648-8     Document Type: Article

References (47)

1. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ (2011) Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. J Neurosci Res 69:337–342. doi:10.1016/j.neures.2010.12.020
2. Bai X, Wey MC, Fernandez E, Hart MJ, Gelfond J, Bokov AF et al (2015) Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy. Pathobiol Aging Age Relat Dis 5:28743. doi:10.3402/pba.v5.28743
3. Beraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA et al (2013) Microglial activation and antioxidant responses induced by the Parkinson’s disease protein alpha-synuclein. J Neuroimmune Pharmacol 8:94–117. doi:10.1007/s11481-012-9401-0
4. Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K et al (2011) alpha-Synuclein alters toll-like receptor expression. Front Neurosci 5:80. doi:10.3389/fnins.2011.00080
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
6. Brun P, Giron MC, Qesari M, Porzionato A, Caputi V, Zoppellaro C et al (2013) Toll-like receptor 2 regulates intestinal inflammation by controlling integrity of the enteric nervous system. Gastroenterology 145:1323–1333. doi:10.1053/j.gastro.2013.08.047
7. Collins LM, Toulouse A, Connor TJ, Nolan YM (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson’s disease. Neuropharmacol 62:2154–2168. doi:10.1016/j.neuropharm.2012.01.028
8. Cui W, Taub DD, Gardner K (2007) qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res 35:D805–D809. doi:10.1093/nar/gkl767
9. Daniele SG, Beraud D, Davenport C, Cheng K, Yin H, Maguire-Zeiss KA (2015) Activation of MyD88-dependent TLR1/2 signaling by misfolded alpha-synuclein, a protein linked to neurodegenerative disorders. Sci Signal 8:ra45. doi:10.1126/scisignal.2005965
10. Deleidi M, Gasser T (2013) The role of inflammation in sporadic and familial Parkinson’s disease. Cell Mol Life Sci 70:4259–4273. doi:10.1007/s00018-013-1352-y
11. Doorn KJ, Moors T, Drukarch B, van de Berg W, Lucassen PJ, van Dam AM (2014) Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson’s disease patients. Acta Neuropathol Commun 2:90. doi:10.1186/s40478-014-0090-1
12. Dzamko N, Geczy CL, Halliday GM (2014) Inflammation is genetically implicated in Parkinson’s disease. Neuroscience. doi:10.1016/j.neuroscience.2014.10.028
13. Fahn S (2003) Description of Parkinson’s disease as a clinical syndrome. Ann NY Acad Sci 991:1–14
14. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164. doi:10.1038/ncb748
15. Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V (2015) Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease. Biochem J 471:323–333. doi:10.1042/BJ20150617
16. Halliday G, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol 115:409–415. doi:10.1007/s00401-008-0344-8
17. Kannarkat GT, Boss JM, Tansey MG (2013) The role of innate and adaptive immunity in Parkinson’s disease. J Parkinson’s Dis 3:493–514. doi:10.3233/JPD-130250
18. Kawai T, Akira S (2011) Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637–650. doi:10.1016/j.immuni.2011.05.006
19. Kim C, Ho DH, Suk JE, You S, Michael S, Kang J et al (2013) Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun 4:1562. doi:10.1038/ncomms2534
20. Kim C, Rockenstein E, Spencer B, Kim HK, Adame A, Trejo M et al (2015) Antagonizing neuronal toll-like receptor 2 prevents synucleinopathy by activating autophagy. Cell Rep 13:771–782. doi:10.1016/j.celrep.2015.09.044
21. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK et al (2010) Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 185:615–623. doi:10.4049/jimmunol.0903480
22. Lippai M, Low P (2014) The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy. Biomed Res Int 2014:832704. doi:10.1155/2014/832704
23. Liu K, Shi N, Sun Y, Zhang T, Sun X (2013) Therapeutic effects of rapamycin on MPTP-induced Parkinsonism in mice. Neurochem Res 38:201–207. doi:10.1007/s11064-012-0909-8
24. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408. doi:10.1006/meth.2001.1262
25. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson’s disease. J Neurosci 30:1166–1175. doi:10.1523/JNEUROSCI.3944-09.2010
26. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291
27. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211:13–16
28. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208–210
29. Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E et al (2014) Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson’s disease. Brain 137:834–848. doi:10.1093/brain/awt367
30. Nagatsu T, Mogi M, Ichinose H, Togari A (2000) Changes in cytokines and neurotrophins in Parkinson’s disease. J Neural Transm Suppl 60:277–290
31. Orr CF, Rowe DB, Halliday GM (2002) An inflammatory review of Parkinson’s disease. Prog Neurobiol 68:325–340
32. Pan T, Rawal P, Wu Y, Xie W, Jankovic J, Le W (2009) Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience 164:541–551. doi:10.1016/j.neuroscience.2009.08.014
33. Piccinini AM, Midwood KS (2010) DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010. doi:10.1155/2010/672395
34. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047
35. Roodveldt C, Labrador-Garrido A, Gonzalez-Rey E, Lachaud CC, Guilliams T, Fernandez-Montesinos R, Benitez-Rondan A et al (2013) Preconditioning of microglia by alpha-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation. PLoS One 8:e79160. doi:10.1371/journal.pone.0079160
36. Sasaki A, Arawaka S, Sato H, Kato T (2015) Sensitive western blotting for detection of endogenous Ser129-phosphorylated alpha-synuclein in intracellular and extracellular spaces. Sci Rep 5:14211. doi:10.1038/srep14211
37. Shechter R, London A, Kuperman Y, Ronen A, Rolls A, Chen A et al (2013) Hypothalamic neuronal toll-like receptor 2 protects against age-induced obesity. Sci Rep 3:1254. doi:10.1038/srep01254
38. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840. doi:10.1038/42166
39. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ (2008) Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging 29:1690–1701. doi:10.1016/j.neurobiolaging.2007.04.006
40. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z et al (2002) Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 169:10–14
41. Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT (2012) PAMPs and DAMPs: signal 0 s that spur autophagy and immunity. Immunol Rev 249:158–175. doi:10.1111/j.1600-065X.2012.01146.x
42. Tanji K, Odagiri S, Miki Y, Maruyama A, Nikaido Y, Mimura J et al (2015) p62 deficiency enhances alpha-synuclein pathology in mice. Brain Pathol 25:552–564. doi:10.1111/bpa.12214
43. van Bergenhenegouwen J, Plantinga TS, Joosten LA, Netea MG, Folkerts G, Kraneveld AD et al (2013) TLR2 & Co: a critical analysis of the complex interactions between TLR2 and coreceptors. J Leukoc Biol 94:885–902. doi:10.1189/jlb.0113003
44. Wales P, Pinho R, Lazaro DF, Outeiro TF (2013) Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration. J Parkinson’s Dis 3:415–459. doi:10.3233/JPD-130216
45. Watanabe Y, Tatebe H, Taguchi K, Endo Y, Tokuda T, Mizuno T et al (2012) p62/SQSTM1-dependent autophagy of Lewy body-like alpha-synuclein inclusions. PLoS One 7:e52868. doi:10.1371/journal.pone.0052868
46. Xilouri M, Brekk OR, Stefanis L (2013) alpha-Synuclein and protein degradation systems: a reciprocal relationship. Mol Neurobiol 47:537–551. doi:10.1007/s12035-012-8341-2
47. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML et al (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 19:533–542. doi:10.1096/fj.04-2751com